Postoperative oliceridine use in patients with advanced age and/or increased BMI was not associated with increased risk of OIRD
Low Incidence of Opioid-Induced Respiratory Depression Observed with Oliceridine Regardless of Age or Body Mass Index: Exploratory Analysis from a Phase 3 Open-Label Trial in Postsurgical Pain
Marek Brzezinski, Gregory B. Hammer, Keith A. Candiotti, Sergio D. Bergese, Peter H. Pan, Michael H. Bourne, Cathy Michalsky, Linda Wase, Mark A. Demitrack, Ashraf S. Habib. Pain & Therapy 2021.
View WebsiteReview of the efficacy and safety of intravenous oliceridine in the treatment of moderate to severe acute pain
Oliceridine in the treatment of moderate to severe acute pain
Sarada S Eleswarpu & Ashraf S Habib. Future Medicine 2021.
DOI: 10.2217/pmt-2020-0087
Oliceridine significantly reduced risk of vomiting and rescue antiemetic use compared to IV morphine in a retrospective analysis
Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials
Timothy L. Beard, Cathy Michalsky, Keith A. Candiotti, Paul Rider, Linda Wase, Ashraf S. Habib, Mark A. Demitrack, Michael J. Fossler, Eugene R. Viscusi
View WebsiteBenefit and Risk Evaluation of Biased μ-Receptor Agonist Oliceridine versus Morphine.
Benefit and Risk Evaluation of Biased μ-Receptor Agonist Oliceridine versus Morphine.
Albert Dahan, C. Jan van Dam, Marieke Niesters, Monique van Velzen, Michael J. Fossler, Mark A. Demitrack, Erik Olofsen. Anesthesiology 2020. doi:
View WebsiteIncidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain: Findings indicate improved safety with oliceridine.
Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain.
Sabry Ayad, Mark A. Demitrack, David A. Burt, Cathy Michalsky, Linda Wase, Michael J. Fossler & Ashish K. Khanna. Clin Drug Investig (2020).
View WebsiteOliceridine Monograph
Oliceridine, a G protein-selective ligand at the μ-opioid receptor, for the management of moderate to severe acute pain
Gan TJ & Wase L. Drugs Today (Barc). 2020 Apr;56(4):269-286. doi: 10.1358/dot.2020.56.4.3107707.
View PDFPhase 3 “Real World” Safety Study for Oliceridine
ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The μ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy
Bergese SD, Brzezinski M, Hammer GB, Beard TL, Pan PH, Mace SE, Berkowitz RD, Cochrane K, Wase L, Minkowitz HS, Habib AS. J Pain Research. 2019, 12: 3113-3126.
DOI: 10.2147/JPR.S217563 [open access]
Pharmacokinetics of IV oliceridine in patients with renal impairment or patients with mild/moderate hepatic impairment- No dose adjustments required
The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine
Nafziger AN, Arscott KA, Cochrane K, Skobieranda F, Burt DA, Fossler MJ. Clin Pharmacol Drug Dev. 2019 Nov 7. doi:10.1002/cpdd.750.[open access]
Oliceridine (TRV130) Phase-3 Pivotal trial in soft-tissue (abdominoplasty) acute pain
APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty
Neil K. Singla, Franck Skobieranda, David G. Soergel, Monica Salamea, David A. Burt, Mark A. Demitrack, Eugene R. Viscusi Pain Pract. 2019 Sep;19(7):715-731
Oliceridine (TRV130) Phase-3 Pivotal trial in hard-tissue (bunionectomy) acute pain
APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy
Eugene R Viscusi, Franck Skobieranda, David G Soergel,Emily Cook, David A Burt, and Neil Singla. J Pain Res. 2019; 12: 927–943.
Oliceridine (TRV130) Phase 2b trial in soft-tissue (abdominoplasty) acute pain
A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty
Neil Singla, Harold S Minkowitz, David G Soergel, David A Burt, Ruth Ann Subach, Monica Y Salamea, Michael J Fossler, and Franck Skobieranda. J Pain Res. 2017; 10: 2413–2424
View WebsiteOliceridine (TRV130) Phase 2 trial in hard-tissue (bunionectomy) acute pain
A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain.
Viscusi ER, Webster L, Kuss M, Daniels S, Bolognese JA, Zuckerman S, Soergel DG, Subach RA, Cook E, Skobieranda F. Pain. 2016 Jan;157(1):264-72.
TRV130- phase I study in healthy volunteers
Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers
Soergel D, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, Skobieranda F, Violin JD, Webster LR. Pain. 2014 Sep;155(9):1829-35
View WebsiteTRV130 – analgesia and ventilatory response to hypercapnia vs. morphine in healthy volunteers
Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers
Soergel DG, Subach RA, Burnham N, et al. Pain. 2014;155(9):1829-1835. doi:10.1016/j.pain.2014.06.011
View WebsiteTRV130- First clinical experience, pharmacokinetics and pharmacodynamics
First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers
Soergel DG, Subach RA, Sadler B, Connell J, Marion AS, Cowan CL, Violin JD, Lark MW. J Clin Pharmacol. 2014 Mar;54(3):351-7.
View WebsiteTRV130-Concept of biased ligand
Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain
Chen XT, Pitis P, Liu G, Yuan C, Gotchev D, Cowan CL, Rominger DH, Koblish M, Dewire SM, Crombie AL, Violin JD, Yamashita DS. J Med Chem. 2013 Oct 24;56(20):8019-31.
View WebsiteTRV-130 preclinical safety results
A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine
DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD. J Pharmacol Exp Ther. 2013 Mar;344(3):708-17.
View Website